Patients Wrestle With High Cost Of Arthritis Medications
Tuesday, April 28, 2015 - 10:50
in Health & Medicine
The first national investigation of Medicare coverage of biologic disease-modifying drugs (DMARDs) found that in starting a single biologic DMARD, patients face more than $2,700 in co-payments each year before receiving relief from catastrophic coverage. During the initial phase of coverage, most people are expected to pay a striking 29.6% of total biologic drugs costs (just under one-third) out-of-pocket, creating an enormous financial burden for patients with chronic, rheumatic diseases such as rheumatoid arthritis. read more